Lobeglitazone is another dual-PPARα/γ agonist able to dampen intrahepatic fat content and ameliorate liver enzymes together with glycemic and lipid profiles in type 2 diabetes patients with NAFLD [130], as it has been demonstrated in a Phase IV trial (NCT02285205). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.